Head to Head Review: Viewray (VRAY) versus Trimedyne (TMED)

Viewray (NASDAQ: VRAY) and Trimedyne (OTCMKTS:TMED) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, analyst recommendations, dividends, earnings, profitability, valuation and institutional ownership.

Risk & Volatility

How to Become a New Pot Stock Millionaire

Viewray has a beta of 0.64, suggesting that its share price is 36% less volatile than the S&P 500. Comparatively, Trimedyne has a beta of -0.85, suggesting that its share price is 185% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Viewray and Trimedyne, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Viewray 0 0 6 0 3.00
Trimedyne 0 0 0 0 N/A

Viewray currently has a consensus price target of $11.58, suggesting a potential upside of 64.77%. Given Viewray’s higher possible upside, research analysts clearly believe Viewray is more favorable than Trimedyne.


This table compares Viewray and Trimedyne’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Viewray -212.02% N/A -60.04%
Trimedyne N/A N/A N/A

Institutional and Insider Ownership

76.2% of Viewray shares are owned by institutional investors. 62.8% of Viewray shares are owned by insiders. Comparatively, 11.1% of Trimedyne shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Viewray and Trimedyne’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Viewray $34.04 million 14.82 -$72.17 million ($1.04) -6.76
Trimedyne $4.70 million 0.21 -$40,000.00 N/A N/A

Trimedyne has lower revenue, but higher earnings than Viewray.


Viewray beats Trimedyne on 7 of the 10 factors compared between the two stocks.

Viewray Company Profile

ViewRay, Inc. designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company’s software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered. MRIdian delivers radiation to the tumor accurately while delivering less radiation to healthy tissue. MRIdian provides real-time imaging that defines the targeted tumor from the surrounding soft tissue and other critical organs during radiation treatment. MRIdian allows physicians to record the level of radiation exposure that the tumor has received and adapt the prescription between fractions as needed.

Trimedyne Company Profile

Trimedyne, Inc. is engaged in the development, manufacturing and marketing of 80 and 30 watt Holmium cold pulsed lasers (Lasers). The Company’s segments include Product, and Service and Rental. It also offers a range of disposable and reusable, fiber optic laser energy delivery devices (Fibers, Needles and Switch Tips) for use in an array of medical applications. Its Lasers, Fibers, Needles and Switch Tips are used in orthopedics, urology, ear, nose and throat surgery, gynecology, gastrointestinal surgery, general surgery and other medical specialties. It markets 80 and 30 watt Holmium Lasers and Side Firing Needles in orthopedics to treat herniated and ruptured spinal discs. Its minimally invasive spinal procedures are performed on an outpatient basis. Its Lasers and Switch Tips are used in orthopedics to treat damage in joints, such as spine and the knee, shoulder, elbow, hip, ankle and wrist, in minimally invasive, outpatient, arthroscopic procedures, called Arthroscopy procedures.

Receive News & Ratings for Viewray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viewray and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply